专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明授权

US5783593A Inhibitors of squalene synthetase and protein farnesyltransferase 失效
标题翻译：角鲨烯合成酶和蛋白质法呢基转移酶的抑制剂
公开(公告)号：US5783593A
公开(公告)日：1998-07-21
申请号：US633262
申请日：1996-04-29
申请人： William R. Baker , Saul H. Rosenberg , Anthony K. L. Fung , Todd W. Rockway , Stephen A. Fakhoury , David S. Garvey , B. Gregory Donner , Stephen J. O'Connor , Rajnandan N. Prasad , Wang Shen , David M. Stout , Gerard M. Sullivan
发明人： William R. Baker , Saul H. Rosenberg , Anthony K. L. Fung , Todd W. Rockway , Stephen A. Fakhoury , David S. Garvey , B. Gregory Donner , Stephen J. O'Connor , Rajnandan N. Prasad , Wang Shen , David M. Stout , Gerard M. Sullivan
IPC分类号： C07C65/24 , C07C65/28 , C07C65/40 , C07C69/94 , C07C229/38 , C07C233/22 , C07C233/65 , C07C233/69 , C07C233/73 , C07C233/87 , C07C235/16 , C07C235/34 , C07C235/42 , C07C235/48 , C07C235/60 , C07C235/84 , C07C237/08 , C07C237/20 , C07C237/32 , C07C251/48 , C07C255/57 , C07C259/10 , C07C271/48 , C07C275/42 , C07C311/08 , C07C311/29 , C07C311/51 , C07C323/59 , C07C327/48 , C07C333/04 , C07D209/16 , C07D213/40 , C07D231/12 , C07D271/10 , C07D271/113 , C07D307/88 , C07D307/89 , C07D309/32 , C07D311/68 , C07D319/06 , C07D333/20 , A61K31/16 , A61K31/19 , A61K31/215 , A61K31/41
CPC分类号： C07D213/40 , C07C229/38 , C07C233/22 , C07C233/65 , C07C233/69 , C07C233/73 , C07C233/87 , C07C235/16 , C07C235/34 , C07C235/42 , C07C235/48 , C07C235/60 , C07C235/84 , C07C237/08 , C07C237/20 , C07C237/32 , C07C251/48 , C07C255/57 , C07C259/10 , C07C271/48 , C07C275/42 , C07C311/08 , C07C311/29 , C07C311/51 , C07C323/59 , C07C327/48 , C07C333/04 , C07C65/24 , C07C65/28 , C07C65/40 , C07C69/94 , C07D209/16 , C07D231/12 , C07D271/113 , C07D307/88 , C07D307/89 , C07D309/32 , C07D311/68 , C07D319/06 , C07D333/20 , C07C2101/14 , C07C2102/08 , C07C2102/10 , C07C2103/18 , C07C2103/74
摘要： The present invention provides a compound of the formula ##STR1## which inhibit squalene synthetase and cholesterol biosynthesis and are useful in the treatment of e.g., hyperlipidaemia, atherosclerosis, or fungal infections, processes for the preparation of the compounds of the invention, intermediates useful in these processes, and pharmaceutical compositions containing the compounds.
摘要翻译：本发明提供抑制角鲨烯合成酶和胆固醇生物合成的式“IMAGE”的化合物，并且可用于治疗例如高脂血症，动脉粥样硬化或真菌感染，制备本发明化合物的方法，可用于这些方法和含有这些化合物的药物组合物。

32. 发明授权

US5631401A Inhibitors of protein farnesyltransferase and squalene synthase 失效
标题翻译：蛋白质法呢基转移酶和角鲨烯合酶抑制剂
公开(公告)号：US5631401A
公开(公告)日：1997-05-20
申请号：US378334
申请日：1995-01-24
申请人： Herman H. Stein , William R. Baker , Anthony K. L. Fung , Saul H. Rosenberg , Todd W. Rockway , Stephen A. Fakhoury , David S. Garvey , B. Gregory Donner , William J. McClellan , Stephen J. O'Connor , Rajnandan Prasad , Wang Shen , Gerard M. Sullivan
发明人： Herman H. Stein , William R. Baker , Anthony K. L. Fung , Saul H. Rosenberg , Todd W. Rockway , Stephen A. Fakhoury , David S. Garvey , B. Gregory Donner , William J. McClellan , Stephen J. O'Connor , Rajnandan Prasad , Wang Shen , Gerard M. Sullivan
IPC分类号： C07C233/58 , C07C233/59 , C07C233/60 , C07C233/62 , C07C233/63 , C07C323/40 , C07D211/16 , C07D211/70 , C07D217/06 , C07D277/34 , C07D295/135 , C07D307/52 , C07D307/58 , C07D307/91 , C07D317/64 , C07D333/20 , C07D333/32 , C07C229/46 , A61K31/19 , A61K31/195
CPC分类号： C07C233/58 , C07C233/59 , C07C233/60 , C07C233/62 , C07C233/63 , C07C323/40 , C07D211/16 , C07D211/70 , C07D217/06 , C07D277/34 , C07D295/135 , C07D307/52 , C07D307/58 , C07D307/91 , C07D317/64 , C07D333/20 , C07D333/32 , C07C2101/02 , C07C2101/04 , C07C2101/08 , C07C2101/14
摘要： The present invention provides a compound of the formula ##STR1## or a pharmaceutically acceptable salt thereof, which are useful in inhibiting protein farnesyltransferase and the farnesylation of the oncogene protein Ras or inhibiting de novo squalene production resulting in the inhibition of cholesterol biosynthesis, processes for the preparation of the compounds of the invention in addition to intermediates useful in these processes, a pharmaceutical composition, and to methods of using such compounds.
摘要翻译：本发明提供式IMA的化合物或其药学上可接受的盐，其可用于抑制蛋白法呢基转移酶和癌基因蛋白Ras的法呢基化或抑制从头角鲨烯生产导致胆固醇生物合成的抑制，除了可用于这些方法的中间体之外，本发明化合物的制备，药物组合物以及使用这些化合物的方法。

33. 发明授权

US09187459B2 Quinazoline-7-ether compounds and methods of use 有权
标题翻译：喹唑啉-7-醚化合物及其使用方法
公开(公告)号：US09187459B2
公开(公告)日：2015-11-17
申请号：US14118200
申请日：2012-05-17
申请人： Wang Shen , Wei Xiao , Jack Maung , Aimin Zhang , Xiaoling Zheng , Zhenzhong Wang , Qingming Guo , Yingguang Li
发明人： Wang Shen , Wei Xiao , Jack Maung , Aimin Zhang , Xiaoling Zheng , Zhenzhong Wang , Qingming Guo , Yingguang Li
IPC分类号： A01N43/54 , A61K31/517 , C07D401/00 , C07D239/72 , C07D405/12 , C07D493/04
CPC分类号： C07D405/12 , C07D493/04
摘要： The invention provides quinazoline-7-ether derivatives, particularly 4-anilinyl-6-butenamido-quinazoline-7-ether derivatives that are inhibitors of the receptor protein tyrosine kinases (RTK). The compounds are useful in the treatment of diseases and disorders where RTK activity is implicated such as a hyperproliferative diseases (e.g., cancer). Also provided are methods of preparation of the quinazoline derivatives and methods of use as therapeutic agents alone or in a drug combination.
摘要翻译：本发明提供了喹唑啉-7-醚衍生物，特别是作为受体蛋白酪氨酸激酶（RTK）抑制剂的4-苯乙烯基-6-丁烯酰氨基 - 喹唑啉-7-醚衍生物。所述化合物可用于治疗涉及RTK活性的疾病和病症，例如过度增殖性疾病（例如癌症）。还提供了制备喹唑啉衍生物的方法和单独使用或作为药物组合用作治疗剂的方法。

34. 发明授权

US08812090B2 Calibration method of electrocardiogram signals and the application program for the same 有权
标题翻译：心电图信号的校准方法和应用程序相同
公开(公告)号：US08812090B2
公开(公告)日：2014-08-19
申请号：US13455332
申请日：2012-04-25
申请人： Tsu-Wang Shen , Shan-Chun Chang
发明人： Tsu-Wang Shen , Shan-Chun Chang
IPC分类号： A61B5/0402
CPC分类号： A61B5/04525 , A61B5/0428 , A61B5/117 , G06K9/00503
摘要： A calibration method of electrocardiogram signals and the application program for the same. The method comprises steps of receiving an uncalibrated/unidentified electrocardiogram signal of a user, calculating the ratio of the distance length of an uncalibrated/unidentified electrocardiogram signal and the distance length of an electrocardiogram template, then generating a trigonometric value which corresponds with a trigonometric projection degree according to the ratio. Next step is to set a characteristic point of the uncalibrated electrocardiogram signal as an axis anchor point of the trigonometric projection for attaining a displacement. Lastly, perform the calibration on the unidentified electrocardiogram signal according to the generated trigonometric value which corresponds with trigonometric projection degree and the attained displacement. Then perform identification comparison of the unidentified electrocardiogram signal and the saved electrocardiogram template for further authorization.
摘要翻译：心电图信号的校准方法及其应用程序。该方法包括以下步骤：接收用户的未校准/未识别的心电图信号，计算未校准/未识别的心电图信号的距离长度与心电图模板的距离长度的比率，然后产生与三角投影对应的三角值程度根据比例。下一步是将未校准的心电图信号的特征点设置为用于获得位移的三角投影的轴锚定点。最后，根据与三角投影度和获得的位移对应的生成的三角值对未识别的心电图信号进行校准。然后对未识别的心电图信号和保存的心电图模板进行识别比较，以进一步授权。

35. 发明申请

US20120183496A1 INHIBITORS OF HEPATITIS C VIRUS POLYMERASE 有权
标题翻译： HEPATITIS C病毒聚合酶抑制剂
公开(公告)号：US20120183496A1
公开(公告)日：2012-07-19
申请号：US13328036
申请日：2011-12-16
申请人： Sam SK Lee , Wang Shen , Xiaoling Zheng , Irina C. Jacobson
发明人： Sam SK Lee , Wang Shen , Xiaoling Zheng , Irina C. Jacobson
IPC分类号： A61K31/4436 , C07D487/04 , A61K31/519 , C07D417/14 , C07D409/14 , A61K31/444 , A61K31/497 , C07D413/14 , C07D498/04 , C07D471/04 , A61K31/4709 , A61K38/21 , A61K31/7056 , A61P31/14 , A61K31/4439 , C07D409/04
CPC分类号： C07D401/04 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/497 , A61K31/519 , A61K31/7056 , A61K38/21 , A61K38/212 , A61K45/06 , C07D401/14 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04
摘要： The present invention provides, among other things, compounds represented by the general Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, R1A, R1B, R2, and R3 are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.
摘要翻译：本发明尤其提供由通式I表示的化合物及其药学上可接受的盐，其中X，Y，R 1A，R 1B，R 2和R 3如本文中的类别和亚类所定义，组合物（例如药物组合物），该化合物可用作丙型肝炎病毒聚合酶的抑制剂，因此可用作例如用于治疗HCV感染的药物。

36. 发明授权

US07989626B2 Modulators of cellular adhesion 有权
标题翻译：细胞粘附的调节剂
公开(公告)号：US07989626B2
公开(公告)日：2011-08-02
申请号：US13021013
申请日：2011-02-04
申请人： Wang Shen , Kenneth Barr , Johan D. Oslob , Min Zhong
发明人： Wang Shen , Kenneth Barr , Johan D. Oslob , Min Zhong
IPC分类号： C07D217/04
CPC分类号： A61K31/4725 , A61K31/472 , A61K31/506 , A61K31/517 , A61K45/06 , C04B35/632 , C07D217/06 , C07D217/16 , C07D217/26 , C07D231/56 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14
摘要： The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
摘要翻译：本发明提供了具有式（I）的化合物及其药学上可接受的衍生物，其中R 1 -R 4，n，p，A，B，D，E，L和AR 1如本文中一般和类别和亚类所述，另外提供其药物组合物及其用于治疗CD11 / CD18家族细胞粘附分子（例如LFA-1）介导的病症的方法。

37. 发明申请

US20110165228A1 Compositions and Methods for Treatment 有权
标题翻译：组合物和治疗方法
公开(公告)号：US20110165228A1
公开(公告)日：2011-07-07
申请号：US13011760
申请日：2011-01-21
申请人： John BURNIER , Thomas GADEK , Min ZHONG , Wang SHEN , Johan D. OSLOB , Kenneth BARR
发明人： John BURNIER , Thomas GADEK , Min ZHONG , Wang SHEN , Johan D. OSLOB , Kenneth BARR
IPC分类号： A61K31/472 , C07D217/26 , A61K9/127 , A61P11/06 , A61P29/00 , A61P17/06 , A61P1/00 , A61P27/02
CPC分类号： A61K31/4725 , A61B3/101 , A61B3/145 , A61K9/0014 , A61K9/0019 , A61K9/0043 , A61K9/0048 , A61K9/0051 , A61K9/0053 , A61K31/197 , A61K31/198 , A61K31/275 , A61K31/341 , A61K31/352 , A61K31/381 , A61K31/40 , A61K31/404 , A61K31/405 , A61K31/4162 , A61K31/4184 , A61K31/4192 , A61K31/44 , A61K31/4709 , A61K31/472 , A61K31/4745 , A61K31/495 , A61K31/496 , A61K31/517 , A61K31/5377 , A61K31/54 , A61K31/541 , A61K33/00 , A61K33/06 , A61K38/07 , A61K38/08 , A61K38/12 , A61K38/1703 , A61K45/06 , C07C279/28 , C07C317/50 , C07D207/06 , C07D217/00 , C07D217/02 , C07D217/06 , C07D217/20 , C07D217/26 , C07D307/52 , C07D333/38 , C07D401/06 , C07D405/06 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , G01N33/5011 , G01N33/5032 , G01N33/5047 , G01N33/566 , G01N33/6872 , G01N2333/705 , G01N2333/70525 , G01N2333/70546 , G01N2500/02 , G01N2500/04 , G01N2500/10 , G01N2500/20 , G01N2800/16 , Y10S514/912 , Y10S514/914
摘要： The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
摘要翻译：本发明提供了用于治疗LFA-1介导的疾病的化合物和方法。特别地，本文描述了LFA-1拮抗剂，并且这些拮抗剂用于治疗LFA-1介导的疾病。在患者被诊断患有LFA-1介导的疾病之后，本发明的一个方面提供LFA-1介导的疾病的诊断和LFA-1拮抗剂的施用。在一些实施方案中，治疗的LFA-1介导的疾病是干眼症。本文还提供了用于鉴定LFA-1拮抗剂的化合物的方法。

38. 发明授权

US07928122B2 Modulators of cellular adhesion 有权
标题翻译：细胞粘附的调节剂
公开(公告)号：US07928122B2
公开(公告)日：2011-04-19
申请号：US12537147
申请日：2009-08-06
申请人： Wang Shen , Kenneth Barr , Johan D. Oslob , Min Zhong
发明人： Wang Shen , Kenneth Barr , Johan D. Oslob , Min Zhong
IPC分类号： A61K31/4709 , A61K31/4725 , C07D217/04 , C07D215/06
CPC分类号： A61K31/4725 , A61K31/472 , A61K31/506 , A61K31/517 , A61K45/06 , C04B35/632 , C07D217/06 , C07D217/16 , C07D217/26 , C07D231/56 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14
摘要： The present invention provides compounds having formula (I); and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
摘要翻译：本发明提供具有式（I）的化合物; 和其药学上可接受的衍生物，其中R 1 -R 4，n，p，A，B，D，E，L和AR 1如本文中一般和本领域和亚类所述，并另外提供其药物组合物及其使用方法用于治疗由细胞粘附分子（例如，LFA-1）的CD11 / CD18家族介导的病症。

39. 发明授权

US07750004B2 Apoptosis promoters 有权
标题翻译：凋亡启动子
公开(公告)号：US07750004B2
公开(公告)日：2010-07-06
申请号：US11482458
申请日：2006-07-07
申请人： Michael D. Wendt , Hong Ding , Sheela A. Thomas , Steven W. Elmore , Wang Shen , Daniel A. Dickman , David Augeri
发明人： Michael D. Wendt , Hong Ding , Sheela A. Thomas , Steven W. Elmore , Wang Shen , Daniel A. Dickman , David Augeri
IPC分类号： A61K31/5375 , C07D265/30
CPC分类号： C07C311/41 , C07C63/48 , C07C63/49 , C07C65/26 , C07C65/28 , C07C205/58 , C07C229/52 , C07C229/56 , C07C233/81 , C07C311/13 , C07C311/18 , C07C311/21 , C07C311/37 , C07C311/44 , C07C323/20 , C07C323/25 , C07C323/62 , C07C2601/08 , C07C2601/14 , C07C2601/18 , C07C2602/10 , C07C2603/18 , C07C2603/74 , C07D207/30 , C07D213/53 , C07D215/12 , C07D215/48 , C07D333/34
摘要： Compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds and methods of treating diseases during which are expressed the Mcl-1 protein are disclosed.
摘要翻译：公开了抑制抗细胞凋亡Mcl-1蛋白活性的化合物，含有该化合物的组合物和治疗疾病的方法，其表达为Mcl-1蛋白。

40. 发明授权

US07714008B2 Heterocyclic GPR40 modulators 失效
标题翻译：杂环GPR40调节剂
公开(公告)号：US07714008B2
公开(公告)日：2010-05-11
申请号：US11900006
申请日：2007-09-06
申请人： Hilary Beck , Paul Dransfield , Zice Fu , Jonathan B. Houze , XianYun Jiao , Todd J. Kohn , SuJen Lai , Jinqian Liu , Jiwen Liu , Zhihua Ma , Julio C. Medina , Michael J. Schmitt , Rajiv Sharma , Wang Shen , Marc Vimolratana , Yingcai Wang , Zhongyu Wang
发明人： Hilary Beck , Paul Dransfield , Zice Fu , Jonathan B. Houze , XianYun Jiao , Todd J. Kohn , SuJen Lai , Jinqian Liu , Jiwen Liu , Zhihua Ma , Julio C. Medina , Michael J. Schmitt , Rajiv Sharma , Wang Shen , Marc Vimolratana , Yingcai Wang , Zhongyu Wang
IPC分类号： A61K31/192 , A61K31/422 , C07C59/11 , C07D261/06
CPC分类号： C07D261/08 , C07D409/12 , C07D413/06 , C07D413/12 , C07D417/12
摘要： The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
摘要翻译：本发明提供了可用于例如治疗受试者的代谢紊乱的化合物。这些化合物具有通式I：其中本文提供变量的定义。本发明还提供了组合物，其包括化合物在制备药物和用于治疗代谢性疾病例如II型糖尿病中的使用方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式